Free Trial
ASX:MXC

Argent BioPharma (MXC) Stock Price, News & Analysis

Argent BioPharma logo

About Argent BioPharma Stock (ASX:MXC)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
2.16 million shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
3.70%
Price Target
N/A
Consensus Rating
N/A

Company Overview

MGC Pharmaceuticals Limited provides phytomedicines worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. In addition, the company provides Irnican that is in preclinical phase for the tetrahydrocannabinol, as well as offers ArtemiC and non-pharma products. Further, it offers consulting services, including clinical research services. MGC Pharmaceuticals Limited was founded in 2014 and is based in Subiaco, Australia.

Receive MXC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Argent BioPharma and its competitors with MarketBeat's FREE daily newsletter.

MXC Stock News Headlines

White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
Argent BioPharma’s Strategic Moves and Collaboration
Argent Biopharma Lists New Shares on ASX
Argent BioPharma Issues New Shares Amidst Strategic Growth
Argent BioPharma Secures Funding for Drug Development
Co-Founder of Argent BioPharma Picks Up 3,721% More Stock
See More Headlines

MXC Stock Analysis - Frequently Asked Questions

Argent BioPharma Limited (ASX:MXC) released its quarterly earnings data on Thursday, February, 28th. The company reported $0.00 earnings per share for the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that Argent BioPharma investors own include NVIDIA (NVDA), Walt Disney (DIS), Grayscale Bitcoin Trust ETF (GBTC), Tesla (TSLA), AbbVie (ABBV), Advanced Micro Devices (AMD) and AstraZeneca (AZN).

Company Calendar

Last Earnings
2/28/2019
Today
5/24/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
ASX:MXC
CIK
N/A
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-17,020,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.32 million
Price / Cash Flow
25.00
Book Value
A$0.04 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.03
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (ASX:MXC) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners